Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 9, 2013, Pages 1113-1122

  Maffioli, Pamela ^a   Fogari, Elena ^a   D'Angelo, Angela ^a   Perrone, Tiziano ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

glibenclamide; insulin sensitivity; pioglitazone; rosuvastatin; steatosis

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSUVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; DIABETIC PATIENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ECHOGRAPHY; FATTY LIVER; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LEG EDEMA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TREATMENT DURATION;

ADIPOKINES; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; FLUOROBENZENES; GLUCOSE CLAMP TECHNIQUE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INTRA-ABDOMINAL FAT; ITALY; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PYRIMIDINES; SUBCUTANEOUS FAT; SULFONAMIDES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881376038     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283608317     Document Type: Article

References (55)

1. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122:1649-1657. (Pubitemid 34533559)
2. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22:1129-1133. (Pubitemid 41224168)
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-1219. (Pubitemid 36538699)
4. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21:3-16. (Pubitemid 32240482)
5. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29:113-119.
6. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011; 31:700-706.
7. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 2005; 129:113-121. (Pubitemid 41002048)
8. Agarwal AK, Jain V, Singla S, Baruah BP, Arya V, Yadav R, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India 2011; 59:351-354.
9. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30:1212-1218. (Pubitemid 46684650)
10. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Nonalcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004; 36:165-173. (Pubitemid 41130632)
11. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51:797-802. (Pubitemid 34760191)
12. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172:899-905. (Pubitemid 40543601)
13. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17:S186-S190. (Pubitemid 34539308)
14. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906. (Pubitemid 40824701)
15. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15:539-543. (Pubitemid 36571048)
16. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002; 123:745-750. (Pubitemid 34977081)
17. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21:71-80. (Pubitemid 32240487)
18. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 2007; 189:W320-W323.
19. Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-g (PPAR-g) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012; 5:272-281.
20. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010; 70:1945-1961.
21. Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther 2010; 35:565-579.
22. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, et al. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother 2009; 63:723-733.
23. Derosa G, Cicero AF, Fogari E, D'Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res 2011; 43:505-512.
24. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88-136.
25. Dodson PM, Lip GY, Eames SM, Gibson JM, Beevers DG. Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified grading system. J Hum Hypertens 1996; 10:93-98. (Pubitemid 26101031)
26. Hayreh SS. Classification of hypertensive fundus changes and their order of appearance. Ophthalmologica 1989; 198:247-260. (Pubitemid 19143852)
27. Walsh JB. Hypertensive retinopathy: description, classification and prognosis. Ophthalmology 1982; 8:1127-1131. (Pubitemid 12003229)
28. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006; 26:2186-2191. (Pubitemid 44465710)
29. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978; 200:21-27. (Pubitemid 8302924)
30. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16:716-730.
31. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8:260-266.
32. Klose S, Borner K. Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978; 15:121-130.
33. Wahlefeld AW. Methods of enzymatic analysis: triglycerides determination after enzymatic hydrolysis. 2nd ed. New York: Academic Press Inc.1974. pp. 18-31.
34. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34:1345-1353.
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
36. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946. (Pubitemid 32756432)
37. Misra A, Garg A. Leptin: its receptor and obesity. J Invest Med 1996; 44:540-548.
38. Zhang M, Tracey K. The Cytokine Handbook. 3rd ed. San Diego: Academic Press; 1988.
39. Song M, Kellum JA. Interleukin-6. Crit Care Med 2005; 33:S463-S465. (Pubitemid 41785989)
40. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated highsensitivity C-reactive protein assay. Clin Chem 1999; 45:2136-2141.
41. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:214-223.
42. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004; 55:729-732. (Pubitemid 38544334)
43. Pontiroli AE, Pizzocri P, Giacomelli M, Marchi M, Vedani P, Cucchi E, et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: comparison with computerized tomography and with anthropometric measurements. Obes Surg 2002; 12:648-651. (Pubitemid 35305743)
44. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York: McGraw-Hill; 1971.
45. Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther 2010; 12:491-501.
46. Yki-Jä rvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
47. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009; 11:1091-1099.
48. Derosa G, Maffioli P. Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 91:265-270.
49. Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 2012; 24:164-171.
50. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279:32345-32353. (Pubitemid 39014687)
51. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103:1372-1379. (Pubitemid 351813900)
52. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103:1036-1042. (Pubitemid 351501089)
53. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 2010; 32:769-775.
54. Zhang W, Wu R, Zhang F, Xu Y, Liu B, Yang Y, et al. Thiazolidinediones improve hepatic fibrosis by activating the adenosine monophosphateactivated protein kinase (ampk) signaling pathway in rats with non-alcoholic steatohepatitis. Clin Exp Pharmacol Physiol 2012; 39:1026-1033.
55. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35:66-75.